BRPI0409402A - derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina - Google Patents
derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosinaInfo
- Publication number
- BRPI0409402A BRPI0409402A BRPI0409402-6A BRPI0409402A BRPI0409402A BR PI0409402 A BRPI0409402 A BR PI0409402A BR PI0409402 A BRPI0409402 A BR PI0409402A BR PI0409402 A BRPI0409402 A BR PI0409402A
- Authority
- BR
- Brazil
- Prior art keywords
- unsubstituted
- mono
- dioxan
- disubstituted
- lower alkyl
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 3
- 108050000203 Adenosine receptors Proteins 0.000 title abstract 2
- 102000009346 Adenosine receptors Human genes 0.000 title abstract 2
- NLFBVFJFZAOVPD-UHFFFAOYSA-N 7-(1,4-dioxan-2-yl)-1,3-benzothiazole Chemical class C1OCCOC1C1=CC=CC2=C1SC=N2 NLFBVFJFZAOVPD-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 benzo [1,3] dioxol-5-yl Chemical group 0.000 abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000532 dioxanyl group Chemical group 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"DERIVADOS DE 7-(¢1,4!DIOXAN-2-IL)-BENZOTIAZOL COMO LIGANTE DE RECEPTOR DE ADENOSINA". A presente invenção refere-se aos compostos da fórmula geral onde R¬ 1¬ é um grupo dioxano, conforme descrito na reivindicação 1 e R¬ 2¬ é - (CH~ 2~)~ n~-Piridin-2,3 ou 4-ila substituída ou não substituída; ou é -(CH~ 2~)~ n~-piperidina-1-ila não substituída ou mono- ou dissubstituída; ou é -(CH~ 2~)~ n~-fenila não substituída ou mono-ou dissubstituída; ou é benzo¢1.3!dioxol-5-ila; ou - (CH~ 2~ )~ n~-morfolinila; ou -(CH~ 2~)~ n~-tetrahidropiran-4-ila; ou -(CH~ 2~)~ n~-O-alquila inferior; ou -(CH~ 2~)~ n~-cicloalquila; ou -(CH~ 2~)~ n~-C(O)-NR<39>R<39><39>; ou -(CH~ 2~)~ n~-2-oxo-pirrolidin-1-ila; ou -(CH~ 2~)~ n~NR<39>R<39><39>; ou -2-oxa-5-aza-iciclo¢2.2.1!heptano-5-ila; ou -1-oxa-8-aza-espiro¢4.5!decano-8-ila; e R<39>e R<39><39> são independentemente um do outro alquila inferior, -(CH~ 2~)~ o~-O-alquila inferior, cicloalquila mono- ou dissubstituída; e n é 0, 1, 2 ou 3; m é O ou 1; e o é 1 ou 2; e aos sais de adição de ácido farmaceuticamente aceitáveis dos mesmos. Foi verificado que os compostos da fórmula geral 1 são ligantes receptores de adenosina com uma boa afinidade em relação ao receptor A~ 2A~ e uma alta seletividade em relação aos receptores A~ 1~- e A~ 3~.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03008038 | 2003-04-14 | ||
| PCT/EP2004/003734 WO2004089949A1 (en) | 2003-04-14 | 2004-04-07 | 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409402A true BRPI0409402A (pt) | 2006-04-25 |
Family
ID=33104055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409402-6A BRPI0409402A (pt) | 2003-04-14 | 2004-04-07 | derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6872833B2 (pt) |
| EP (1) | EP1615919B1 (pt) |
| JP (1) | JP4426569B2 (pt) |
| KR (1) | KR100700422B1 (pt) |
| CN (1) | CN100447140C (pt) |
| AR (1) | AR043845A1 (pt) |
| AT (1) | ATE370947T1 (pt) |
| AU (1) | AU2004228193B2 (pt) |
| BR (1) | BRPI0409402A (pt) |
| CA (1) | CA2520852C (pt) |
| CL (1) | CL2004000761A1 (pt) |
| CO (1) | CO5640107A2 (pt) |
| DE (1) | DE602004008447T2 (pt) |
| ES (1) | ES2291868T3 (pt) |
| MX (1) | MXPA05011102A (pt) |
| NO (1) | NO20054794L (pt) |
| RU (1) | RU2005135154A (pt) |
| TW (1) | TW200427685A (pt) |
| WO (1) | WO2004089949A1 (pt) |
| ZA (1) | ZA200508180B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2581454A1 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| US7756037B2 (en) * | 2006-08-14 | 2010-07-13 | Cisco Technology, Inc. | Oversubscription of guaranteed bandwidth |
| DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
| CA2903572A1 (en) * | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| PT3661941T (pt) * | 2017-08-01 | 2023-03-16 | Merck Patent Gmbh | Derivados tiazolopiridina como antagonistas do recetor de adenosina |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001281817B2 (en) | 2000-06-21 | 2005-11-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| EP1491541B1 (en) * | 2001-03-30 | 2007-01-24 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| US6734179B2 (en) | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
-
2004
- 2004-03-30 US US10/812,736 patent/US6872833B2/en not_active Expired - Fee Related
- 2004-04-07 MX MXPA05011102A patent/MXPA05011102A/es active IP Right Grant
- 2004-04-07 JP JP2006505050A patent/JP4426569B2/ja not_active Expired - Fee Related
- 2004-04-07 KR KR1020057019469A patent/KR100700422B1/ko not_active Expired - Fee Related
- 2004-04-07 BR BRPI0409402-6A patent/BRPI0409402A/pt not_active IP Right Cessation
- 2004-04-07 CN CNB2004800098019A patent/CN100447140C/zh not_active Expired - Fee Related
- 2004-04-07 ES ES04726119T patent/ES2291868T3/es not_active Expired - Lifetime
- 2004-04-07 EP EP04726119A patent/EP1615919B1/en not_active Expired - Lifetime
- 2004-04-07 TW TW093109634A patent/TW200427685A/zh unknown
- 2004-04-07 RU RU2005135154/04A patent/RU2005135154A/ru not_active Application Discontinuation
- 2004-04-07 DE DE602004008447T patent/DE602004008447T2/de not_active Expired - Lifetime
- 2004-04-07 AU AU2004228193A patent/AU2004228193B2/en not_active Ceased
- 2004-04-07 WO PCT/EP2004/003734 patent/WO2004089949A1/en not_active Ceased
- 2004-04-07 CA CA2520852A patent/CA2520852C/en not_active Expired - Fee Related
- 2004-04-07 AT AT04726119T patent/ATE370947T1/de active
- 2004-04-08 CL CL200400761A patent/CL2004000761A1/es unknown
- 2004-04-12 AR ARP040101209A patent/AR043845A1/es not_active Application Discontinuation
-
2005
- 2005-10-10 ZA ZA200508180A patent/ZA200508180B/en unknown
- 2005-10-11 CO CO05103899A patent/CO5640107A2/es not_active Application Discontinuation
- 2005-10-18 NO NO20054794A patent/NO20054794L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004089949A1 (en) | 2004-10-21 |
| EP1615919A1 (en) | 2006-01-18 |
| EP1615919B1 (en) | 2007-08-22 |
| CL2004000761A1 (es) | 2005-02-04 |
| JP4426569B2 (ja) | 2010-03-03 |
| US6872833B2 (en) | 2005-03-29 |
| CA2520852C (en) | 2011-10-11 |
| RU2005135154A (ru) | 2006-06-27 |
| ATE370947T1 (de) | 2007-09-15 |
| US20040204584A1 (en) | 2004-10-14 |
| CN1774437A (zh) | 2006-05-17 |
| AR043845A1 (es) | 2005-08-17 |
| KR100700422B1 (ko) | 2007-03-28 |
| ES2291868T3 (es) | 2008-03-01 |
| DE602004008447D1 (de) | 2007-10-04 |
| NO20054794L (no) | 2005-10-27 |
| CA2520852A1 (en) | 2004-10-21 |
| DE602004008447T2 (de) | 2008-05-21 |
| AU2004228193B2 (en) | 2009-07-23 |
| ZA200508180B (en) | 2007-03-28 |
| TW200427685A (en) | 2004-12-16 |
| CN100447140C (zh) | 2008-12-31 |
| AU2004228193A1 (en) | 2004-10-21 |
| JP2006522765A (ja) | 2006-10-05 |
| MXPA05011102A (es) | 2005-12-12 |
| KR20050111795A (ko) | 2005-11-28 |
| CO5640107A2 (es) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ishida et al. | Antitumor agents 201.1 Cytotoxicity of harmine and β-carboline analogs | |
| BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
| BRPI0606644A2 (pt) | derivados de 4-carboxamida tiazola | |
| CR8530A (es) | Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
| CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
| BRPI0606895A2 (pt) | novos compostos com efeito terapêutico | |
| BRPI0606367A2 (pt) | derivados espirocetais e composições farmacêuticas compreendendo os mesmos | |
| BRPI0407493A (pt) | derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6 | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| BRPI0517461A (pt) | compostos farmacêuticos | |
| BRPI0506719A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014006283A2 (pt) | novos derivados de dihidroquinolina-2-ona | |
| BRPI0507620A (pt) | monÈmeros de acrilamida contendo funcionalidades hidroxila e silìcio e polìmeros feitos a partir dos mesmos | |
| BR0307268A (pt) | Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1 | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| BR112015000019A2 (pt) | corantes azo dispersos, processo para preparação dos mesmos e uso dos mesmos | |
| AR064640A1 (es) | DERIVADOS DE PIRIDO[2, 3-D]PIRIMIDIN-4, 7(3H, 8H)-DIONA, METODOS PARA SU PREPARACION E INTERMEDIARIOS DE SINTESIS, COMPOSICIONES FARMACEUTICAS, KIT DE ELEMENTOS Y ARTíCULO MANUFACTURADO QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR M | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| BR0305247A (pt) | Processo de preparação de copolìmeros de etileno | |
| NO20081206L (no) | Isoquinolines derivatives as IGF -1R inhibitors | |
| BRPI0409402A (pt) | derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina | |
| BRPI0615248A2 (pt) | derivado tendo atividade agonista de ppar | |
| BR112012026458A2 (pt) | derivados de pirazolopiridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |